ALGS — ALIGOS THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ALGS?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their ALGS position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +1 tracked investor added or increased positions last quarter (Ken Griffin)
- +1 tracked investors reported holding ALGS at their latest filing
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ALIGOS THERAPEUTICS INC (ALGS)
ALIGOS THERAPEUTICS INC (ALGS) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $483,093. Across recent filings, tracked investors recorded 4 new positions, 1 increased, 1 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ALGS
How many top investors track ALGS
Only 1 tracked investor report this position.
ALGS Ownership Composition
How ALIGOS THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ALGS
1 tracked investor has since exited this position — listed separately below.
- Ken GriffinSep 30, 2026Citadel AdvisorsShares11.5KValue$65K% Portfolio0.00%
Previously held ALGS
These investors reported ALGS in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Izzy Englander | Millennium Management | 12.3K | $88.8K | Jun 30, 2025 |
Recent activity
- New$65KNov 16, 2026
- Sold$0(-100.00%)Nov 14, 2024
- $88.8KAug 14, 2025
- New$109.6KAug 14, 2025
- Reduced$101K(-32.16%)Nov 14, 2025
- Increased$483.1K(402.75%)Feb 17, 2026
- Sold$0(-100.00%)Aug 14, 2026
- $108.4KMay 15, 2024
Frequently asked questions
- How many institutional investors hold ALGS?
- 1 tracked institutional investor disclosed a position in ALGS (ALIGOS THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ALGS?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ALGS, valued at $483,093.
- Did institutional ownership of ALGS increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 1 increased, 1 reduced, and 2 fully exited ALGS.
- Where does this ALGS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.